Abiopharma

🔍 Zandi Mark (Director)

Company: MGIC INVESTMENT CORP (MTG)

Report Date: 2026-08-20

Detailed Transactions and Holdings:

• Acquired 28 shares of Common Stock (Direct)
  Date: 2026-08-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 33,974.95 | transaction_form_type: 4 | Footnotes: F1
• Acquired 268 shares of Share Units (Derivative)
  Date: 2026-08-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 48,921.50 | transaction_form_type: 4 | Footnotes: F2, F3, F6, F4, F5

Footnotes:

• F1: Dividends paid on Restricted Stock Units awarded under the Issuer's Omnibus Incentive Plan. No price was paid by the reporting person for them.
• F2: The reporting person participates in the MGIC Investment Corporation Deferred Compensation Plan for Non-Employee Directors under which units corresponding to shares of Common Stock of the Issuer ("Share Units") are awarded to the reporting person and/or acquired through compensation deferral.
• F3: These Share Units do not have a specified dollar-denominated exercise or conversion price. Their value is based, on a one-for-one basis, on the price of the Issuer's common stock on the New York Stock Exchange.
• F4: These Share Units are settled in cash, on a specified date, unless a qualified election for later distribution is made by the reporting person.
• F5: These Share Units do not expire on a fixed date. They are settled in cash on a specified date, unless a qualified election for later distribution is made by the reporting person.
• F6: These Share Units were acquired through phantom dividend reinvestment and no price was paid by the reporting person for the Share Units.